Council of Scientific and Industrial Research

Aditya Konar

Santu Bandyopadhyay

Siddhartha Roy

Bholanath Paul

Arun Bandyopadhyay

Bikas Chandra Pal

Anirban Manna

Jayaraman Vinayagam

Sanjit Kumar Mahato

Indrani Choudhury Mukherjee

Jhillu Singh Yadav

Samir Bhattacharya

Bikash Chandra Pal

Rakesh Kamal Johri

Subhash Chander Sharma

Balaram Ghosh

Balram Ghosh

Dipyaman Ganguly

Radha Krishna Palakodety

Mohua Mukherjee

Vasanta Madhava Sharma Gangavaram

Gurdarshan Singh

Mabalirajan Ulaganathan

Parasuraman Jaisankar

Nahid Ali

Sib Sankar Roy

Malabika Datta

Tanima Banerjee

Dipak Kar

Tulika Mukherjee

Mumu Chakraborty

Swapan Kumar Mandal

Tanushree Biswas

Debaprasad Jana

Bir Bhanu Giri

Santu Bandopadhyay

Debleena Dey

Churala Pal

Kausik Paul

Amlanjyoti Dhar

Shampa Mallick

Israr Ahmed

Arjun Ram

Ulaganathan Mabalirajan

Arun Bandopadhyay

Jayashree Bagchi Chakraborty

Jaydeep Chaudhuri

Roma Sinha

Pradyot Bhattacharya

Deba Prasad Jana

Sushovan Chowdhury

Jaisankar Parasuraman

Jayashree Bagchi Chakrabotry

Srabanti Rakshit

Labanya Mandal

Sibabrata Mukhopadhyay

Jayachree Bagchi Chakrabotry

The present invention describes a novel bivalent helically constrained peptide targeted against S100B that is an effective anti-cancer drug against cancers that over-express S100B. This helix mimetic targeted against S100B induces rapid apoptosis in cancer cells that over-express a calcium binding protein S100B through simultaneous inhibition of key growth pathways including activation of p53.

High affinity bivalent helically constrained peptide against cancer

The present invention relates to compounds of general formula 1 for the treatment of bronchial asthma by inhibition of IL-4 or IL-5 pathway inhibition. The present invention also relates to the use of compound of general formula 1 for the treatment of bronchial by inhibition of IL-4 or IL-5 pathway. The present invention also relates to the method of treating asthma by inhibition of IL-4 or IL-5 pathway by administration of compound or said composition through oral, intranasal, route or by inhalation to a mammal in need thereof. Compound of general formula 1 may be used for reducing perivascular and peribronchial inflammation.

Substituted cathechols as inhibitors of IL-4 and IL-5 for the treatment of bronchial asthma

The present invention relates to compounds of general formula 1 for the treatment of malignancy by inhibition of PI3-Akt pathway and or induction of NO. The present invention also relates to the use of compound of general formula 1 for the treatment of malignancy by inhibition of PI3-Akt pathway and or induction of NO. The present invention further relates to a method of treating malignancy by inhibition of PI3-Akt pathway and or induction of NO by administration of compound or said composition to a mammal in need thereof.

Inhibitors of phosphatidylinositol-3-kinase (PI3) and inducers of nitric oxide (NO)

The present invention relates to a method for the treatment of bronchial asthma and chronic obstructive pulmonary disease (COPD) comprising administering to the patient suffering from asthma and COPD an effective dose of carbazole derivatives or salt thereof, optionally along with pharmaceutically acceptable excipients. Structural formula of the compounds of general formula 1 useful as phosphodiesterase-4 (PDE-4) enzyme inhibitors, inhibitor for signalling molecule for the treatment of asthma and asthma related diseases is given below:  Herbal route for the isolation of compound of general formula 1 from the bark of plantand chemical route for the preparation of such compounds from basic compounds such as vanillin is also reported.

Method for treatment of bronchial asthma

The present invention relates to a method of preventing and/or treating diabetes type 2, also, it relates to a method of augmenting Glut4 phosphorylation and Glut4 translocation to a target cell membrane to enhance insulin signal in a signal transduction pathway; further, it relates to a simplified and inexpensive process of obtaining extract and thereafter selectively, its active n-butanol fraction and active molecule Lupinoside PA (LPA), useful in preventing and/or treating diabetes type 2; and lastly, a pharmaceutical composition thereof.

Herbal extract and compound lupinoside and its analogues as anti-diabetic type II drugs from plant Pueraria tuberosa

Growing community of inventors

Kolkata, India

Aditya Konar